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Abstract
We developed and validated a two-gene signature that predicts prognosis in previously-untreated chronic lymphocytic
leukemia (CLL) patients. Using a 65 sample training set, from a cohort of 131 patients, we identified the best clinical models
to predict time-to-treatment (TTT) and overall survival (OS). To identify individual genes or combinations in the training set
with expression related to prognosis, we cross-validated univariate and multivariate models to predict TTT. We identified
four gene sets (5, 6, 12, or 13 genes) to construct multivariate prognostic models. By optimizing each gene set on the
training set, we constructed 11 models to predict the time from diagnosis to treatment. Each model also predicted OS and
added value to the best clinical models. To determine which contributed the most value when added to clinical variables,
we applied the Akaike Information Criterion. Two genes were consistently retained in the models with clinical variables: SKI
(v-SKI avian sarcoma viral oncogene homolog) and SLAMF1 (signaling lymphocytic activation molecule family member 1;
CD150). We optimized a two-gene model and validated it on an independent test set of 66 samples. This two-gene model
predicted prognosis better on the test set than any of the known predictors, including ZAP70 and serum b2-microglobulin.
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Introduction
Gene expression profiling studies of CLL using microarray
technology have examined differential gene expression with
respect to a wide variety of prognostic factors, including the
somatic mutation status of the immunoglobulin heavy chain
variable region (IGHV) genes, clinical stage, cytogenetic abnor-
malities, and others [1,2,3,4,5,6,7]. These studies have shown that
CLL cases share a characteristic gene expression profile, and that
prognostic subtypes are distinguishable by small subsets of genes.
Gene expression profiling results also have yielded lists of genes
that are potential biomarkers of prognosis, many of which have
shown promise in the clinical setting. For example, expression of
ZAP70 has been found to correlate with unmutated IGHV somatic
mutation status and a poor clinical outcome [3,4,8,9,10,11]. These
studies have focused on different prognostic factors. Thus, it is not
surprising that they have identified independent sets of potential
biomarkers, which need to be validated in order to be clinically
useful. Towards this goal, in a previous study we developed and
validated predictive models of prognosis in untreated CLL
patients. We first produced a quantitative real-time polymerase
chain reaction assay on microfluidics cards (MF-QRT-PCR) using
a panel of candidate biomarkers linked to IGHV somatic mutation
status. These markers were selected by re-analyzing raw data from
previously published microarray studies [1,2,3,4,12]. We then
applied this assay to untreated CLL patient samples, and
demonstrated that we could predict IGHV somatic mutation status
with 90% accuracy based on the expression of as few as three
genes [13].
In the current study, we sought to develop and validate
predictive models based on a wide range of reported clinical,
cytogenetic, and molecular prognostic markers, including IGHV
somatic mutation status. We began by re-analyzing previously
published microarray studies [5,6,7,14,15,16,17,18]. Our study
group was 131 previously-untreated CLL patients for whom
samples were available for analysis. We first identified the best
clinical models to predict time-to-event outcomes, i.e., time-to-
treatment (TTT) and overall survival (OS), in a training set of 65
samples. We then sought to identify individual genes or
combinations of genes, in the training set, in which expression
was related to prognosis. By performing extensive cross-validation
of both univariate and multivariate models to predict TTT, we
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be used to construct multivariate prognostic models. By applying
statistical methods to optimize each of these four sets of genes on
the training set, we constructed 11 models to predict the interval
between diagnosis and first treatment. Each model also predicted
OS and added value to the best clinical models. To determine
which genes contributed the most value when added to the clinical
variables, we applied the Akaike Information Criterion [19]. Two
genes were consistently retained in the models in the presence of
the clinical variables: SKI (v-SKI avian sarcoma viral oncogene
homolog) and SLAMF1 (signaling lymphocytic activation molecule
family member 1; CD150). We then optimized a two-gene
predictive model and validated its performance in an independent
test set of 66 CLL patient samples. This model was validated
successfully, and predicted prognosis on the test set better than any
of the existing clinical predictors.
Results
Patient characteristics
The characteristics of 131 previously untreated CLL patients
are summarized in Table 1. We collected the following clinical
and laboratory parameters: age at diagnosis, gender, Rai stage,
bulky lymphadenopathy (splenomegaly $8 cm below the costal
margin or lymph nodes $5 cm), white blood cell (WBC),
prolymphocyte, and platelet counts, hemoglobin level, serum
lactate dehydrogenase (LDH) and b2-microglobulin levels,
hypogammaglobulinemia, CLL score [20], surface immunoglob-
ulin (IG) light chain isotype, CD38, IGHV somatic mutation
status, ZAP70 protein expression, and cytogenetic complexity
(defined as $3 abnormalities). With the exception of the WBC
count, there were no statistically significant differences between
the 65 samples used for the training set and the 66 samples used
for the validation set. The median time from diagnosis to sample
collection for the 131 patients was 28 months (range 1–211
months); there was no significant difference (p=0.77) in time
from diagnosis to sample collection between the training set
(median 26 months) and the test set (median 29 months,
Table 1).
Clinical Predictors of TTT and OS in CLL
A flow diagram of the complete statistical analysis is presented
in Figure S1. We first sought to identify the best clinical models
to predict time-to-event outcomes in the training set of 65
samples assayed on cards A and B. In order to determine the best
model that we could construct from pre-existing markers, we
analyzed all of the clinical and laboratory variables listed in
Table 1. We performed time-to-event analyses using two
different starting points: time of diagnosis and time of sample
collection. We also used two different endpoints: TTT and OS.
Based on these starting and endpoints, we constructed four
models. We found that the best model to predict the time from
diagnosis to treatment incorporated the (log) serum LDH level,
IG light chain isotype, and platelet count. We refer to the
numerical predictions from this model as the ‘‘clinical score’’.
The best model to predict time from sample collection to
treatment incorporated the IGHV somatic mutation status, IG
light chain isotype, platelet count, WBC count, and (log) serum
b2-microglobulin level. The best model to predict OS from
diagnosis incorporated age at diagnosis and IGHV somatic
mutation status. The best model to predict OS from sample
collection incorporated age at diagnosis, IGHV somatic mutation
status, and (log) serum b2 microglobulin level. After we
constructed these clinical models, we assessed how MF-QRT-
PCR assay data might add to the accuracy of the predictions.
(The complete computer scripts used to analyze the data are
available at http://bioinformatics.mdanderson.org/Supplements/
Microfluidics/Prognosis.) [21].
Identification of Gene Markers of Prognosis (Feature
Selection)
Our next goal was to identify individual genes or combinations
of genes that were related to prognosis in the training set. We
began by re-analyzing the data from cards A and B in light of the
updated clinical data, but focused on genes that had been chosen
for inclusion on the validation card C. In order to identify robust
prognostic markers of TTT, we performed four univariate
analyses (one gene at a time) on the training data from the 65
patients assayed on cards A and B. We performed analyses using
two starting points: diagnosis and sample collection. We
incorporated gene expression either as a continuous predictor of
outcome or as a dichotomous variable. In univariate models, we
found at least 15 genes that predicted TTT (Table 2). For the
most part, the same genes were significant predictors under all four
conditions: time from diagnosis, gene expression as a dichotomous
variable; time from diagnosis, gene expression as a continuous
variable; time from sample collection, gene expression as a
dichotomous variable; time from sample collection, gene expres-
sion as a continuous variable.
We also used the training data to cross-validate univariate and
multivariate models to predict TTT. We repeatedly and randomly
selected 50 of the 65 training samples and used them to fit
univariate models. Genes for which the geometric mean of the
four univariate p-values was ,0.03 were selected for inclusion in a
multivariate model that combined continuous gene expression
levels to predict the time from diagnosis to treatment or time from
sample collection to treatment. We used AIC to decide which
genes to retain in the best multivariate models (Table 2). We
identified two genes retained in $25% of the cross-validation
multivariate models to predict time from diagnosis to treatment,
SKI and SLAMF1. Six genes, SKI, CD14, NT5C2, OAS3, NRIP1,
and SLAMF1, were retained in $25% of the cross-validation
multivariate models to predict time from sample collection to
treatment.
We repeated this analysis using OS as the outcome instead of
TTT (Table S1). The ability of individual genes to predict OS
was weak, with only four genes (CD14, WSB2, TNFRSF8, and
NT5C2) being significant in $10% of the cross-validation
univariate models. In general, significance levels for the ability to
predict OS were lower than those for TTT because there were
many fewer events. After a median follow up of more than 8 years
(101 months, range 10–271 months) from diagnosis, out of 131
patients 109 had required treatment and 31 had died (Table 1). It
is possible with additional follow-up that we would be able to
predict OS. In this analysis, we did not take into account clinical
covariates that are associated with prognosis in previously
untreated CLL patients. Thus, we repeated the analysis in order
to determine which genes added predictive power to the best
clinical models, described above. After accounting for known
clinical factors, we found no single gene that added to our ability to
predict either TTT or OS. However, the genes SLAMF1, NRIP1,
SKI, NT5C2, FGFR1, CD14, and CRY1 showed borderline
statistical significance in the training set, depending on the start
time (diagnosis or sample collection) or endpoint (treatment or
survival). This finding suggested that appropriate combinations of
gene expression might provide prognostic value that added to the
existing clinical variables.
SKI and SLAMF1 Predict Time-to-Treatment in CLL
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By evaluating the number of times a gene was selected as significant
in the cross-validation analyses performed above, we identified four
sets of genes, containing 5, 6, 12, or 13 genes, that could be used to
construct multivariate prognostic models (Figure 1). Starting with
each of these sets of genes, we constructed Cox proportional hazards
models to predict the time from diagnosis to treatment. We used both
AIC and BIC to build optimal models that used the fewest number of
genes from each set. We repeated the process starting from the time of
sample collection. This process produced 11 different models
(Table 3), each of which was highly significant for predicting the
time from diagnosis to treatment on the training set.
Table 1. Clinical and Laboratory Features.*
All Patients
(n=131)
Training
(n=65)
Test Set
(n=66) p value
{
Age at diagnosis (years) Median, years
(range)
56.7
(26.7, 80.9)
56.1
(26.7, 80.1)
58.5
(37.6, 80.9)
0.12
Gender Male, n (%)
Female, n (%)
81 (61.8)
50 (38.2)
42 (64.6)
23 (35.4)
39 (59.1)
27 (40.9)
0.59
Rai stage 0–2, n (%)
3–4, n (%)
102 (77.9)
29 (22.1)
54 (83.1)
11 (16.9)
48 (72.7)
18 (27.3)
0.21
Splenomegaly
(cm below costal margin)
,8 cm, n (%)
$8 cm, n (%)
126 (95.5)
5( 4 . 5 )
63 (96.9)
2 (3.1)
63 (95.5)
3 (4.5)
0.99
WBC count
{ #150610
9/L, n (%)
.150610
9/L, n (%)
118 (90.1)
13 (9.9)
63 (96.9)
2 (3.1)
55 (83.3)
11 (16.7)
0.02
Hgb (g/dL)
{ Median
(range)
12.9
(8.2, 17.4)
12.9
(10.0, 17.0)
12.9
(8.2, 17.4)
0.59
Prolymphocytes (% of WBC) Median
(range)
3.0
(0.0, 21.0)
4.0
(0.0, 21.0)
2.5
(0.0, 15.0)
0.19
Platelets (610
9/L)
{ Median
(range)
168
(39, 476)
168
(39, 379)
169
(60, 476)
0.31
LDH (U/L)
{ Median
(range)
526
(274, 1818)
527
(338, 1313)
517
(274,1818)
0.10
b2M (mg/L)
{ (n=130) ,4, n (%)
$4, n (%)
98 (75.4)
32 (24.6)
45 (70.3)
19 (29.7)
53 (80.3)
13 (91.7)
0.22
Serum Ig
{ (n=118) Decreased, n (%)
Normal, n (%)
69 (58.5)
49 (41.5)
30 (52.6)
27 (47.4)
39 (63.9)
22 (36.1)
0.26
CLL score (n=113) Atypical, n (%)
Typical, n (%)
32 (28.3)
81 (71.7)
18 (31.6)
39 (68.4)
14 (25.0)
42 (75.0)
0.53
Surface IgL (n=125) Kappa, n (%)
Lambda, n (%)
78 (62.4)
47 (37.6)
36 (60.0)
24 (40.0)
42 (64.6)
23 (35.4)
0.71
CD38
{ (n=124) Low, n (%)
High, n (%)
98 (79.0)
26 (21.0)
50 (83.3)
10 (16.7)
48 (75.0)
16 (25.0)
0.28
IGHV SM status (n=130) Mutated, n (%)
Unmutated, n (%)
67 (51.5)
63 (48.5)
36 (55.4)
29 (44.6)
31 (47.7)
34 (52.3)
0.48
ZAP70 (n=113) Positive, n (%)
Negative, n (%)
62 (54.9)
51 (45.1)
32 (59.3)
22 (40.7)
30 (50.8)
29 (49.2)
0.45
Karyotype
{ (n=94) Simple, n (%)
Complex, n (%)
82 (87.2)
12 (12.8)
41 (93.2)
3 (6.8)
41 (82.0)
9 (18.0)
0.13
Time of follow up from diagnosis Median, months
(range)
101.3
(9.6, 271.3)
109.2
(9.6–252.4)
93.1
(28.3–271.3)
0.46
Time from diagnosis to sample Median, months
(range)
27.5
(0.7–211.5)
26.0
(0.7–151.9)
29.2
(1.0–211.5)
0.77
Time from diagnosis to first treatment Median, months
(range)
28.8
(0.7, 211.5)
28.0
(0.7–198.3)
30.7
(1.0–211.5)
0.84
Overall survival at final follow up n (%) 100 (76.3) 45 (69.2) 55 (83.3) 0.10
Abbreviations: WBC, white blood cell; Hgb, hemoglobin; Prolymphs, prolymphocytes; LDH, serum lactate dehydrogenase; b2M, serum b2 microglobulin; serum Ig,
serum immunoglobulin levels; surface IgL, surface immunoglobulin light chain isotype; IGHV SM status, immunoglobulin heavy chain variable region gene somatic
mutation status.
*Rai stage, splenomegaly, WBC count, Hgb, Prolymphs, Platelets, LDH, b2M, serum Ig were determined at the time the sample was obtained. The CLL score, surface IgL,
IGHV SM status, ZAP70, and karyotype were determined on samples obtained before treatment was initiated.
{All p values were calculated using the two-sided Fisher’s Exact test except for age in years, which was calculated using the two-sided t-test, and time-to-event
parameters (log-rank test).
{The normal ranges are: WBC, 4–11610
9/L; Hgb, 14.0–18.0 g/dL, platelets, 140–440610
9/L; LDH, 313–618 U/L; b2M, 0.7–1.8 mg/L; serum Ig, IgM 29–214 g/dL, IgA 74–
327 g/dL, IgG 624–1680 g/dL. Serum Ig are considered decreased (hypogammaglobulinemia) if $2 immunoglobulin fractions are below the normal range. CD38 is low
if ,30% of CD19+ cells express CD38, and high if $30% of CD19+ express CD38. Karyotypes are considered simple if the number of abnormalities is ,3, and complex if
the number is $3.
doi:10.1371/journal.pone.0028277.t001
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for each patient, as a linear combination of gene expression values
(Table S2). In general, the GP scores were strongly correlated
from one model to another. The GP scores were also highly
significant for predicting the time from sample collection to
treatment on the training set. We evaluated the GP scores from
each model for their ability to predict OS. As continuous variables,
the GP scores from all 11 models were significant for predicting
OS (Table 3).
Gene prognostic scores were independent of the best clinical
model of prognosis described above and, therefore, contributed
additional information (Table 3). To determine which genes in
each GP score contributed the most value when added to the
clinical variables, we again applied AIC to models that added the
gene sets to the clinical variables in order to predict time from
diagnosis to treatment or OS. The only genes that were
consistently retained in the models, in the presence of the clinical
variables, were SKI and SLAMF1. Both genes were expressed in all
Table 2. Ability of genes to predict time-to-treatment on the training set.
Cox proportional hazards Cross-validation
Log-rank p-values % of times selected
Time from Diagnosis Time from Sample Collection Diagnosis Sample
Dichotomous Continuous Dichotomous Continuous Univariate Multivariate
SKI 0.00070 0.00153 0.00054 0.00040 96.7 68.3 77.3
NT5C2 0.00327 0.00932 0.00045 0.00142 91.3 34.0 43.3
AICDA 0.00329 0.02869 0.00059 0.00595 83.7 13.3 14.3
SLAMF1 0.03603 0.00390 0.02166 0.00032 82.7 45.3 26.0
CD14 0.01806 0.01375 0.00229 0.00033 76.3 12.7 58.3
FGL2 0.05126 0.02619 0.00104 0.00050 75.7 18.3 23.7
NUDC 0.01311 0.01185 0.01277 0.00844 58.7 16.0 8.0
NRIP1 0.09115 0.01747 0.00887 0.00047 53.3 7.0 26.0
EGR3 0.11961 0.01697 0.02460 0.00120 47.0 15.0 9.7
OAS3 0.03989 0.01868 0.02203 0.00527 43.7 18.0 40.7
MLXIP 0.01028 0.00922 0.03763 0.02238 41.3 23.7 7.7
TPST2 0.02604 0.11673 0.00166 0.01538 39.3 8.7 6.7
GZMK 0.10461 0.47112 0.00425 0.01093 19.7 3.7 19.0
TRIB2 0.04825 0.03755 0.03220 0.03645 18.7 4.3 3.3
BLNK 0.21545 0.01056 0.17736 0.01136 15.3 10.7 9.7
ATF4 0.03024 0.04587 0.06964 0.14722 9.0 8.3 3.7
ZAP70 0.05281 0.72270 0.01290 0.20473 3.0 1.3 0.3
CCL5 0.31346 0.20183 0.11853 0.10792 2.7 2.7 2.7
FLNB 0.33042 0.16040 0.12236 0.07366 2.0 1.0 0.0
FGFR1 0.20586 0.13564 0.19548 0.22199 2.0 2.0 2.0
ZBTB20 0.32892 0.26458 0.08767 0.05625 1.0 0.7 1.0
GFI1 0.12424 0.27589 0.11658 0.23475 0.7 0.0 0.0
ATRX 0.53365 0.21520 0.23976 0.12142 0.3 0.3 0.3
SEPT10 0.84619 0.57552 0.61241 0.07739 0.3 0.0 0.3
LPL 0.30342 0.19845 0.19664 0.08380 0.3 0.0 0.0
WSB2 0.42500 0.97415 0.15628 0.38180 0.0 0.0 0.0
TNFRSF8 0.60838 0.69192 0.28498 0.52499 0.0 0.0 0.0
RIOK2 0.83187 0.30138 0.96935 0.16604 0.0 0.0 0.0
P2RX1 0.28422 0.20501 0.15201 0.06186 0.0 0.0 0.0
LDOC1 0.48194 0.97673 0.15223 0.62795 0.0 0.0 0.0
LASS6 0.72274 0.72844 0.48064 0.52066 0.0 0.0 0.0
CRY1 0.27369 0.44715 0.12731 0.23697 0.0 0.0 0.0
COBLL1 0.59439 0.53532 0.77744 0.86219 0.0 0.0 0.0
CD86 0.94053 0.82897 0.84059 0.18854 0.0 0.0 0.0
BCL7A 0.99125 0.79130 0.46758 0.57526 0.0 0.0 0.0
BANK1 0.98999 0.36153 0.60229 0.81261 0.0 0.0 0.0
ANXA2 0.55803 0.44614 0.79069 0.65462 0.0 0.0 0.0
doi:10.1371/journal.pone.0028277.t002
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to treatment.
Training a Two-Gene Prognostic Model
Since SKI and SLAMF1 were the genes that were most consistently
retained as predictors of time from diagnosis to treatment in the
presence of clinical variables, we developed and tested a two-gene
model based on SKI and SLAMF1 for predicting TTT or OS. We
computed the GPscore forthe two-gene model fromtheDD-Ctvalues
for the genes SKI and SLAMF1 using the formula: GP score=0.847
SKI+0.158 SLAMF1. To dichotomize the score, we defined a cutoff at
the median value (0.022) on the training samples. Scores greater than
the median were considered high; scores less than or equal to the
median were considered low. When applied to the training set, we
found that the GP score based on the two-gene model using SKI and
SLAMF1 effectively predicted both time from diagnosis to treatment
(p=0.000127), and time from sample collection to treatment
(p=9.08610
26). The GP score also showed the correct trend to
predict OS from the time of diagnosis, (p=0.0554).
Validation of a Two-Gene Prognostic Model
Based on these results, we sought to determine if the GP score
based on the two-gene model effectively predicted time from
diagnosis to treatment in an independent test set of 66 samples.
Figure 1. Cross-validation of gene predictors on the training set. (A) Histogram of the number of times each gene was statistically significant
among 300 assessments of univariate models. (B) Histogram of the number of times each gene was retained in a multivariate model to predict time-
to-treatment either from diagnosis or from sample collection (300 each). (C) Sorted probabilities that a gene was significant in a univariate model.
Gaps in the figure identify a six-gene and a twelve-gene subset. (D) Sorted probabilities that a gene was retained in a multivariate model. Gaps in the
figure identify a five-gene and a thirteen-gene subset.
doi:10.1371/journal.pone.0028277.g001
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diagnosis to treatment, both as a continuous score (p=1.78610
28)
and as a dichotomous variable (p=6.47610
26)( Figure 2). The
same GP score predicted OS after diagnosis on the validation
dataset as a dichotomous variable (p=0.0182), but was only
marginally significant as a continuous variable (p=0.0994).
Moreover, the same GP score also predicted time from sample
collection to treatment, both as a continuous variable (p=0.00098)
and as a dichotomous variable (p=0.00164).
Finally, we sought to determine if the two-gene model added to
the clinical model in an independent test set. Because we had
found previously that the clinical score was a poor predictor of
TTT in this data set, we re-fit the clinical model on the test set and
then compared it to the GP score. The GP score, derived from the
training data, remained the best predictor of TTT, although the
platelet count provided additional prognostic ability. We also
compared the GP score to individual clinical predictors. The GP
score was at least as effective as IGHV somatic mutation status at
predicting TTT, and the GP score more effectively predicted TTT
than any of the other variables in Table 1, including Rai stage,
gender, serum b2 microglobulin level, WBC count, CD38 or
ZAP70 expression, and cytogenetic complexity (Figure 3).
Discussion
The goal of this study was to develop and validate models of
gene expression that would contribute prognostic information to
predict TTT for patients with previously untreated CLL. This
study has yielded a two-gene model that adds prognostic
information independent of and in addition to known clinical data.
We analyzed all data using an extremely rigorous training and
validation design. Extensive model building, with cross-validation,
was applied to the training data set of 65 samples. To avoid over-
fitting, we tested only the best gene-expression-based model (the
model with SKI and SLAMF1) on an independent set of 66 samples
that had been assayed on a new printing (Card C) of the
microfluidics cards. The highly significant p-values on this
independent set provide powerful evidence supporting the clinical
utility of the two-gene model. We applied similar rigorous
statistical methods to the clinical data. For these analyses, we
used standard statistical methods, i.e., Cox proportional hazards
with stepwise AIC to choose the variables that should be retained
in the model. Somewhat surprisingly, the predictive model based
purely on the clinical variables did not validate; this result,
unfortunately, is one of the possible consequences whenever one
assesses combinations of many variables to construct predictive
models, and is the reason that separate training and validation
datasets are required. However, because numerous clinical factors
have been shown previously to be significant predictors of
prognosis in many studies of patients with CLL, we extended
our analysis to pose a greater challenge to the two-gene model.
Using the two-gene model that we learned from the training set
to make predictions (GP scores) on the validation set, we compared
the predictions from the two-gene model to each of the individual
clinical factors listed in Table 1. Even in this setting, the two
gene-model predicted TTT in the validation set better than all
other factors, except, possibly, for IGHV somatic mutation status.
While further studies will be necessary to determine whether
mutation status or the two-gene model is ultimately a better
predictor of TTT in CLL patients, our results on the independent
Table 3. Genes retained in multivariate models to predict time from diagnosis to treatment in the training dataset.
Gene Set M6 M6 M6,SAM
{ M5 M6,SAM
{
M5* M12 M6* M13 M12* M13*
Optimizer
{ AIC BIC AIC AIC,BIC BIC AIC,BIC AIC,BIC
SKI Yes (c) Yes (c) Yes Yes (c) Yes (c) Yes (c) Yes (c) Yes (c) Yes (c) Yes (c) Yes
NT5C2 Yes Yes Yes Yes Yes Yes – Yes – Yes Yes
SLAMF1 – Yes (c) – – Yes (c) Yes (c) Yes (c) Yes (c) Yes (c) Yes (c) Yes (c)
CD14 – – Yes – Yes Yes – Yes – Yes Yes
FGL2 – – – – – – Yes Yes Yes Yes Yes
OAS3 – – – Yes – Yes – – – Yes Yes
NUDC – – – – – – Yes – Yes Yes Yes
MLXIP – – – – – – Yes – Yes Yes Yes
AICDA – – – – – – – Yes – Yes Yes
NRIP1 – – – – – – – – – Yes Yes
EGR3 – – – – – – – – – Yes Yes
BLNK – – – – – – – – Yes – Yes
T P S T 2 ––– –– ––––Y e s –
GZMK – – – – – – – – – – Yes (c)
Predicts OS?
1 0.0234 0.0233 0.0036 0.0139 0.0094 0.0048 0.0383 0.0132 0.0473 0.0087 0.0307
Adds to CM?
" 0.034 0.016 0.031 0.030 0.015 0.016 0.011 0.012 0.0046 0.0031 0.0027
Abbreviations: M, model; AIC, Akaike Information Criterion; BIC, Bayes Information Criterion; SAM, sample collection; CM, clinical model.
*Four different sets of genes were chosen as starting points, containing 5, 6, 12, or 13 genes.
{We applied stepwise forward-backward methods to each gene set to optimize either AIC or BIC.
{Two gene sets optimized predictions of the time from sample collection to treatment; all others looked at the time from diagnosis to treatment.
1Log rank P value to test, via Cox proportional hazards, if a continuous score derived to predict time-to-treatment also predicts overall survival.
"P-value computed from a chi-squared test of whether the continuous score adds value to the existing clinical predictors.
(c) Individual genes that remained significant when added to the existing clinical predictors.
doi:10.1371/journal.pone.0028277.t003
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predictors of prognosis in previously untreated patients with CLL.
In order to identify candidate biomarkers of prognosis, we chose
genes that had been identified either in previous gene expression
profiling studies that we performed or from our review of the
literature. However, SKI was identified serendipitously. The goals
of our initial studies were to evaluate the MF-QRT-PCR assay
technology, and to develop statistical methods to normalize and
analyze the data [1,13,14]. Studies indicate that no single
housekeeping gene works well in all studies, and that better results
are obtained by using multiple housekeeping genes for normali-
zation [14,22]. Based on an initial experiment using samples
obtained from nine previously-untreated CLL patients (four with
unmutated and five with mutated IGHV), we selected eight
potential control genes that appeared to show little variability
across the samples, one of which was SKI [14]. However, in a
subsequent study of 29 CLL samples (14 mutated and 15
unmutated), SKI was found to vary significantly across the samples
[13]. Thus, it was eliminated from our list of endogenous control
genes, but was retained on Card A and included in our analysis as
a candidate biomarker of prognosis.
Our studies indicate that higher expression levels of SKI and
SLAMF1 mRNA are associated with a longer TTT in patients with
previously untreated CLL. SKI, located on chromosome 1p36.3,
encodes the nuclear protein homolog of the avian sarcoma viral (v-
ski) oncogene [23,24]. SKI is expressed ubiquitously at low levels in
adult and embryonic tissues [24,25]. During embryogenesis SKI
appears to regulate cellular differentiation, particularly of neural
tissues and skeletal muscle. In adult tissues, SKI participates in
diverse cellular functions including proliferation, differentiation,
cell cycle progression, and apoptosis. Ski also has been reported to
be relatively overexpressed in murine memory B cells compared
germinal center B cells, suggesting that it contributes to memory B
cell differentiation [26]. Depending upon the context, overexpres-
sion of SKI can result in either transformation or terminal
differentiation [25]. Thus, SKI can function either as a proto-
oncogene or as a tumor suppressor gene. These divergent
functions likely reflect its ability to interact with a variety of
transcription factor partners [25]. Consistent with its role as an
oncogene, SKI expression is increased in different cancer types,
including esophageal squamous cell carcinoma [27], melanoma
[28], and acute myeloid leukemias [29,30]. One of its most
important mechanisms of action is to negatively regulate TGF-b
signaling by interacting with Smad proteins and repressing their
transcriptional activity [31]. SKI also blocks differentiation by
inhibiting RARa signaling in some subtypes of acute myeloid
leukemia [29,30]. However, SKI may also function as a tumor
suppressor gene [23]. Shinagawa and colleagues demonstrated
that Ski-deficient heterozygous mice developed hematologic
malignancies, following challenge with a chemical carcinogen,
predominantly T-cell lymphomas, but also B-cell lymphoma and
myeloid leukemias [23]. They hypothesized that the tumor
suppressor activity of SKI results from its ability to mediate
transcriptional repression by other known tumor suppressors,
namely Mad and Rb, which interact with multiple target genes to
negatively regulate cell cycle progression. In this study, we found
that increased SKI expression is associated with a better outcome,
raising the possibility that it may function as a tumor suppressor
gene in some cases of CLL.
SLAMF1 (CD150) is one of a family of nine (SLAMF1–9)
glycoprotein receptors that belong to the IG supergene family, all
of which reside on chromosome 1q23 [32]. Members of this family
regulate hematopoietic stem cell differentiation, leukocyte adhe-
sion and activation, and humoral immune responses. In general,
members of this family act as self-ligands. Most, including
SLAMF1, are transmembrane proteins that contain tyrosine
residues within their cytoplasmic domains. These tyrosine residues
interact with adaptor proteins that connect the receptors to signal
transduction networks. One of the adaptors, SLAM-associated
protein (SAP), encoded by the SH2D1A gene, is mutated in
patients with X-linked lymphoproliferative syndrome [33,34,35].
SLAMF1 is expressed on thymocytes, memory T cells, B cell
Figure 2. Kaplan-Meier plots of the time from diagnosis to treatment stratified by the gene prognostic (GP) score (a linear
combination of the expression of SKI and SLAMF1) in (A) the training set and (B) the validation set.
doi:10.1371/journal.pone.0028277.g002
SKI and SLAMF1 Predict Time-to-Treatment in CLL
PLoS ONE | www.plosone.org 7 December 2011 | Volume 6 | Issue 12 | e28277SKI and SLAMF1 Predict Time-to-Treatment in CLL
PLoS ONE | www.plosone.org 8 December 2011 | Volume 6 | Issue 12 | e28277subsets, mature dendritic cells and platelets [32,36,37]. Its
expression is rapidly induced on naı ¨ve T cells and B cells after
activation [32,36,37]. It also serves as a cellular receptor for the
measles virus [32]. SLAM family members are required for
germinal center formation and for generation of humoral immune
responses and memory B cells [32,38,39]. Studies of SLAMF1
expression in human B-cell subsets have demonstrated that its
expression varies with stage of differentiation [38,40]. SLAMF1
expression increases during B-cell development [40]. However,
SLAMF1 expression by memory B cells may vary depending upon
the compartment studied. In human spleen, Good and colleagues
[38] found that SLAMF1 was absent from memory B cells. In
contrast, De Salort and colleagues [40] reported that SLAMF1
was highly expressed on memory B cells isolated from tonsil, but
showed bimodal expression on splenic memory B cells.
In a previous meta-analysis of three gene expression profiling
studies, we found that SLAMF1 was relatively overexpressed in
normal peripheral blood B cells compared to CLL cells [2,3,12].
We subsequently determined that SLAMF1 is relatively overex-
pressed in mutated compared to unmutated untreated CLL
patients [13]. Similarly, Mittal and colleagues [41] identified
SLAMF1 as one of 27 genes that was overexpressed in CLL cases
with cytogenetic markers of good prognosis (del(13q) and normal)
relative to cases with cytogenetic markers of poor prognosis
(del(11q) and +12), as assessed by fluorescence in situ hybridization
(FISH). Taken together, these findings suggest that signaling
through SLAMF1 may be dysregulated in CLL cells compared to
normal peripheral blood B cells, and that the degree of
dysregulation may be reflected in more aggressive clinical
behavior.
As a first step in this study, we constructed clinical models of
prognosis for our CLL study group. As expected, we found that
the best models incorporated combinations of well-known markers
of prognosis: age at diagnosis, WBC count, serum LDH and serum
b2 microglobulin levels, and IGHV somatic mutation status.
However, we were surprised to find that the best model to predict
TTT from the time of sample collection also incorporated the IG
light chain isotype. In particular, we found that patients with
somatically-mutated kappa-positive CLL had a statistically
significantly longer TTT (p=0.00032) than the other three
subgroups, i.e., unmutated kappa-positive, mutated lambda-
positive, and unmutated lambda-positive CLL, which showed
similar TTTs (data not shown). Stated differently, patients with
somatically mutated lambda-positive CLL had a TTT that was
similar to CLL patients with unmutated IGHV. An early study,
which assessed surface IG expression by flow cytometry in
untreated patients with B-cell non-Hodgkin lymphomas found
that patients with lambda-positive CLL/small lymphocytic
lymphoma had shorter survival than patients with kappa-positive
CLL [42]. However, a much larger study performed several years
later found no difference in survival between newly-diagnosed
CLL patients whose cells expressed kappa compared to lambda
[43]. Neither study evaluated TTT and both were based on older
lymphoma classification schemes that lacked precision. Our
patient cohort contained an equal number of IG kappa and
lambda light chain expressing cases (62 cases each). The mutated
cases were almost evenly divided between kappa (33 cases) and
lambda (29 cases); the unmutated cases more often showed kappa
expression (44 kappa-positive vs. 18 lambda-positive, p=0.064). A
similar kappa predominance among unmutated cases has been
described previously [44]. Unlike that study, we did not find a
lambda predominance in the mutated cases. One possible
explanation that could account for the shorter TTT that we
observed for somatically mutated lambda-positive CLL patients is
that our patient cohort might contain an excess of cases that use
IGHV families associated with a poor prognosis regardless of
mutation status, i.e., VH3-21, VH3-48, and VH3-53 [45,46]. Cases
that use these families also tend to show a lambda light chain bias.
However, of the 10 cases that used one of these IGHV families in
our patient cohort, only four were somatically mutated and
expressed lambda light chain. Thus, we are unable to account for
the association of lambda immunoglobulin light chain expression
and shorter TTT based on IGHV family use.
In summary, the goal of this study was to develop a clinically
useful assay based on the expression of a limited set of protein
coding genes to determine prognosis in patients with previously
untreated CLL. The two-gene signature that we have identified is
similar to other multi-gene panels (Oncotype DxH assays) that are
currently used to predict the likelihood of chemotherapy benefit
and recurrence risk in early stage breast cancer and the recurrence
risk in colon cancer (http://www.genomichealth.com/Oncoty-
peDX/Index.aspx). We believe this two-gene signature predicts
TTT at least as well as current markers of prognosis in untreated
CLL patients. Additional studies using this two-gene model
performed on larger patient cohorts will be helpful to further
assess clinical utility.
Materials and Methods
Ethics statement, sample collection, and RNA preparation
Samples were collected from 131 previously untreated CLL
patients at The University of Texas M.D. Anderson Cancer
Center (Houston, TX, USA) after obtaining written informed
consent. The study was approved by The University of Texas
M.D. Anderson Cancer Center Institutional Review Board and
conducted according to the principles expressed in the Declaration
of Helsinki. Clinical and routine laboratory data were obtained
from review of the medical records. Peripheral blood was collected
and processed as described previously [47]. Total RNA was
extracted using two rounds of guanidine isothiocyanate/ phenol:
chloroform extraction (TRIzolH Reagent, Life Technologies, Inc.,
Gaithersburg, MD) according to the manufacturer’s instructions.
Total RNA was further purified using RNeasy spin columns
(Qiagen, Valencia, CA) and its quality assessed by agarose gel
electrophoresis. Total RNA was reverse transcribed using random
hexamers and a First-Strand cDNA Synthesis kit (Amersham
Pharmacia Biotech, Inc., Piscataway, NJ). The cDNA was used for
all subsequent PCR assays.
Evaluation of the IGHV somatic mutation status
The somatic mutation status of the IGHV genes was assessed as
described previously, with minor modifications [47]. Briefly, we
amplified cDNA using a mixture of six 59 VH primers that amplify
all seven VH families and a 39 constant region primer (Cm) in the
presence of reaction buffer, deoxynucleotide triphosphates
(2.5 mM), and HotStar Taq DNA polymerase (Qiagen Sciences).
Following incubation at 94uC for 15 minutes cDNA was amplified
for 30 cycles (94uC for 1 minute, 56uC for 1 minute, and 72uC for
Figure 3. Kaplan-Meier plots of time from diagnosis to treatment in the validation set, showing the interactions between the SKI-
SLAMF1 score and (A) gender, (B) Rai stage, (C) WBC count, (D) serum b2-microglobulin level, (E) CD38, (F) IGHV somatic mutation
status, (G) ZAP70, (H) cytogenetic complexity, and (I) clinical score.
doi:10.1371/journal.pone.0028277.g003
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used a mixture of VH Framework 1 primers and a 39 JH consensus
primer (59-AACTGAGGAGACGGTGACC-39) Two indepen-
dent PCR reactions were performed for each sample. The gel-
purified PCR products were sequenced directly using the 39 PCR
primer and an ABI 3700 or 3730 DNA Analyzer (Applied
Biosystems, Branchburg, NJ). In order to determine the degree of
IGHV somatic mutation, patient sequences were aligned with
germline sequences in VBASE II [48]. The somatic mutation
status was designated as unmutated if there were ,2% mutations
(.98% homology to germline sequences), or as mutated if there
were $2% mutations (#98% homology to germline sequences)
compared with germline sequences [49].
Assessment of ZAP70 protein expression
Expression of ZAP70 was assessed either by immunohistochem-
istry or flow cytometry. Immunohistochemical staining was
performed using routinely fixed and processed paraffin-embedded
tissue sections of bone marrow core biopsy and/or aspirate clot
specimens and a specific monoclonal antibody (Upstate Cell
Signaling Systems, Lake Placid, NY, USA) [8,11]. The flow
cytometry assay for ZAP70 was performed by the Chronic
Lymphocytic Leukemia Research Consortium laboratory as
described previously [50].
Design and production of the custom QRT-PCR
microfluidics card
We printed 384-well custom microfluidics cards (MF) with gene-
specific forward and reverse primers and TaqManH probes to
assess candidate biomarkers, and performed semi-quantitative
real-time polymerase chain reaction (QRT-PCR) assays, as
described previously [13,14]. Also included were five endogenous
control genes, 18S rRNA, GAPD, PGK1, GUSB, and ECE-1, that
spanned the dynamic range of the microfluidics cards. We used
three different cards, designated A, B, and C, printed with
candidate biomarkers of prognosis in CLL. Card A was printed
with 88 candidate biomarkers of IGHV somatic mutation status
[1,2,3,4,12,13]. Card B was printed with 91 candidate biomarkers
associated with prognostic factors other than IGHV somatic
mutation status (Table S3) [5,6,7,14,15,16,17,18]. Card C, which
was used for validation, was printed with 37 candidate biomarkers
that appeared to predict TTT based on a preliminary analysis of
cards A and B, and the five endogenous control genes (Table S4).
We assayed 65 training patient samples on cards A and B, and 66
validation patient samples on card C.
Statistical Methods
The MF-QRT-PCR assay data were processed as described
previously [13,14]. Briefly, data from each card were quantified
separately using the SDS 2.1 software package (Applied Biosys-
tems, Carlsbad, CA) with an automatic baseline and a manual
threshold of 0.10 to record the cycle thresholds, CT. Next, DCT
values were computed by subtracting the mean of the five
endogenous control genes: 18S rRNA, GAPD, PGK1, GUSB, and
ECE-1. Statistical analyses were performed in version 2.11 of R, a
freely available statistical software package (http://cran.r-project.
org/). Differences in clinical and laboratory covariates between
training and validation datasets were tested using unequal-
variance two-sample t-tests for continuous variables and Fisher’s
Exact Test for dichotomous (binary) variables.
Kaplan-Meier estimates were used to plot survival curves.
Univariate time-to-event analyses (for TTT and for OS) were
conducted using Cox proportional hazards models and tested for
significance using the log rank test. In order to select the best sets
of predictors in multivariate models, we began with a Cox
proportional hazards model that incorporated all variables. We
then used a stepwise backward-forward algorithm to optimize
either the Akaike Information Criterion (AIC) or the Bayes
Information Criterion (BIC) [19]. The best multivariate models
were selected based on AIC. (Models selected using BIC were
almost always identical to those selected by AIC; when they
differed, the AIC model included an additional factor, which we
chose to retain.) We extensively cross-validated potential models
on the training set before applying the best potential model to the
validation dataset. The complete computer scripts used to analyze
the data are available at http://bioinformatics.mdanderson.org/
Supplements/Microfluidics/Prognosis [21].
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